(XZE5) Xtrackers II EUR Corporate - Ratings and Ratios

Exchange: SW • Country: Switzerland • Currency: CHF • Type: Etf • ISIN: LU2178481649

Corporate Bond, Short Term, European, Investment Grade, Bonds

Description: XZE5 Xtrackers II EUR Corporate

The Xtrackers II EUR Corporate Bond Short Duration SRI PAB UCITS ETF 1C CHF is an exchange-traded fund that tracks the Morningstar EZN Corp Bd GR EUR index, providing exposure to short-duration EUR corporate bonds. The fund is domiciled in Switzerland and has a substantial asset base, with AUM of approximately 1.37 billion CHF.

As a corporate bond ETF, it is designed to offer a relatively stable source of returns with lower volatility compared to equity investments. The short duration aspect suggests that the fund is positioned to minimize interest rate risk, making it potentially more resilient in a rising rate environment. The SRI (Sustainable Reporting Initiative) and PAB (Paris-Aligned Benchmark) labels indicate that the fund adheres to certain environmental, social, and governance (ESG) criteria, making it suitable for investors with sustainability considerations.

To further evaluate this ETF, key performance indicators (KPIs) such as yield, duration, and credit quality can be considered. A yield comparison with other similar ETFs or the underlying index can provide insights into its income generation potential. The funds duration, while indicated as short, should be quantified to understand its sensitivity to interest rate changes. Credit quality analysis, including the proportion of investment-grade versus high-yield bonds, is crucial for assessing the funds risk profile.

From a technical analysis perspective, the ETFs price action and moving averages suggest a relatively stable trend. The SMA20 being slightly above the current price indicates a potential resistance level, while the SMA50 is very close to the current price, suggesting a balance between bullish and bearish forces. The significant gap between the SMA200 and the current price indicates a longer-term uptrend. The ATR (Average True Range) is relatively low, indicating low volatility, which is consistent with the expectation for a bond ETF.

Additional Sources for XZE5 ETF

Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

XZE5 ETF Overview

Market Cap in USD 1,723m
Category EUR Corporate Bond
TER 0.16%
IPO / Inception 2020-07-23

XZE5 ETF Ratings

Growth Rating -28.0
Fundamental -
Dividend Rating 0.0
Rel. Strength 6.28
Analysts -
Fair Price Momentum 40.31 CHF
Fair Price DCF -

XZE5 Dividends

Currently no dividends paid

XZE5 Growth Ratios

Growth Correlation 3m 67.9%
Growth Correlation 12m -6%
Growth Correlation 5y -40.4%
CAGR 5y -8.13%
CAGR/Max DD 5y -0.38
Sharpe Ratio 12m -0.32
Alpha -15.19
Beta 0.028
Volatility 4.03%
Current Volume 0k
Average Volume 20d 0k
Stop Loss 42.5 (-3%)
What is the price of XZE5 shares?
As of July 16, 2025, the stock is trading at CHF 43.81 with a total of 0 shares traded.
Over the past week, the price has changed by -0.44%, over one month by -0.62%, over three months by -0.35% and over the past year by +0.73%.
Is Xtrackers II EUR Corporate a good stock to buy?
Probably not. Based on ValueRay´s Analyses, Xtrackers II EUR Corporate (SW:XZE5) is currently (July 2025) not a good stock to buy. It has a ValueRay Growth Rating of -27.98 and therefor a somwhat technical negative rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of XZE5 is around 40.31 CHF . This means that XZE5 is currently overvalued and has a potential downside of -7.99%.
Is XZE5 a buy, sell or hold?
Xtrackers II EUR Corporate has no consensus analysts rating.
What are the forecasts for XZE5 share price target?
According to our own proprietary Forecast Model, XZE5 Xtrackers II EUR Corporate will be worth about 43.5 in July 2026. The stock is currently trading at 43.81. This means that the stock has a potential downside of -0.62%.
Issuer Target Up/Down from current
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 43.5 -0.6%